LPTX - Leap Therapeutics, Inc.
| Previous Close | 1.5600 |
| Open | 1.5600 |
| Bid | 1.6000 x 2200 |
| Ask | 1.8300 x 800 |
| Day's Range | 1.5600 - 1.8200 |
| 52 Week Range | 0.5730 - 3.3000 |
| Volume | 569,202 |
| Avg. Volume | 558,106 |
| Market Cap | 43.067M |
| Beta (5Y Monthly) | 2.46 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.5440 |
| Earnings Date | Nov 13, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.58 |
- PR Newswire
Leap Therapeutics Announces Closing of Previously Announced Equity Financing
Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of its previously announced equity financing to issue 1,421,801 shares of newly designated Series A mandatorily convertible preferred stock to a lead institutional investor, at a price of $10.54 per share, and an aggregate of 1,137,442 shares of newly designated Series B mandatorily convertible preferred stock to BeiGene and Perceptive Advisors, at a price of $10.55 per share. The preferred stock price reflects a common stock equivalent price of $1.055 per share, the closing price for Leap's common stock on the Nasdaq Global Market on the day of pricing, January 2, 2020 and, in the case of the Series A mandatorily convertible preferred stock, reflects a per share reduction equal to the exercise price of the pre-funded warrant issued upon conversion of the Series A mandatorily convertible preferred stock. The holder of Series A mandatorily convertible preferred stock also received a share of a newly designated special voting preferred stock that will entitle it to elect one member of Leap's Board of Directors.
- Zacks
Leap Therapeutics Surges on License Agreement With BieGene
Leap Therapeutics (LPTX) signs agreement with China-based BieGene granting the latter rights to develop its pipeline candidate, DKN-01. It also signs equity financing deals worth $27 million.
- American City Business Journals
Cash-strapped biotech signs deal with Chinese drugmaker BeiGene
A small Cambridge biotech is getting a much-needed infusion of cash, signing what its CEO called a “transformative” collaboration deal with Chinese drugmaker BeiGene Ltd.
- PR Newswire
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing
Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted immuno-oncology therapeutics, and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly-targeted and immuno-oncology drugs for the treatment of cancer, today announced an exclusive option and license agreement for the clinical development and commercialization of DKN-01, Leap's anti-Dickkopf-1 (DKK1) antibody, in Asia (excluding Japan), Australia, and New Zealand. Leap will retain exclusive rights for the development, manufacturing, and commercialization of DKN-01 for the rest of the world. In addition, Leap announced entering into an agreement for a $27 million equity financing with BeiGene and two institutional investors.
- Benzinga
The Daily Biotech Pulse: Amarin Gets Unanimous Backing For Vascepa Expansion, BeiGene's Blood Cancer Drug Gets Approval
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on Nov. 14) 10X Genomics Inc (NASDAQ: TXG )(IPOed Sept. 12) 89bio ...
- PR Newswire
Leap Therapeutics Reports Third Quarter 2019 Financial Results
- DKN-01 data continues to show robust activity, including a monotherapy complete response, in cancer patients with high DKK-1 expression and Wnt signaling alterations - De-prioritizing further development ...
- Zacks
Zacks.com featured highlights include: Columbia Sportswear, American Woodmark, DICK'S Sporting, Alder and Leap
Zacks.com featured highlights include: Columbia Sportswear, American Woodmark, DICK'S Sporting, Alder and Leap
- Zacks
Use Rising P/E Strategy to Grab 5 Winning Stocks
Cross the age-old barrier of low P/E investing. bet on these five stocks that boast rising P/E.
- Simply Wall St.
Do Directors Own Leap Therapeutics, Inc. (NASDAQ:LPTX) Shares?
The big shareholder groups in Leap Therapeutics, Inc. (NASDAQ:LPTX) have power over the company. Insiders often own a...
- PR Newswire
Leap Therapeutics to Present Updated Data for DKN-01 Monotherapy and Paclitaxel Combination at the 2019 International Gynecologic Cancer Society Annual Global Meeting
- DKN-01 Monotherapy Patient with an Ongoing Complete Response - Enhanced PFS in patients with Wnt Activating Mutations and DKK1 -high Tumors CAMBRIDGE, Mass. , Sept. 17, 2019 /PRNewswire/ -- Leap Therapeutics, ...
- PR Newswire
Leap Therapeutics to Present at Upcoming Investor Conferences
CAMBRIDGE, Mass. , Sept. 4, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. ...
- PR Newswire
Leap Therapeutics Reports Second Quarter 2019 Financial Results
- Positive data from DKN-01 plus KEYTRUDA® (pembrolizumab) combination study - First patients enrolled in TRX518 plus BAVENCIO® (avelumab) and cyclophoshamide combination study CAMBRIDGE, Mass. , Aug. ...
- PR Newswire
Leap Presents Positive Clinical Results for the Combination of DKN-01 plus Keytruda® and Provides DKN-01 Program Update
-- Enhanced survival outcomes in DKK1 -high gastroesophageal junction and gastric cancer patients - -- DKK1 -high biomarker enables future patient selection - -- Live conference call and webcast with clinical ...
- PR Newswire
Leap Therapeutics to Host Conference Call to Provide DKN-01 Program Update
Conference call and webcast to be held August 6, 2019 at 8:30 a.m. ET CAMBRIDGE, Mass. , July 25, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology company focused on developing ...
- PR Newswire
Leap Therapeutics Announces Common Stock Purchase Agreements For Up to $21 Million with Lincoln Park Capital
CAMBRIDGE, Mass., July 11, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced it has entered into common stock purchase agreements for up to $21 million with Lincoln Park Capital Fund, LLC ("LPC"), a Chicago-based institutional investor and current shareholder. Under a purchase agreement dated July 11, 2019, LPC agreed to purchase $1,000,000 of Leap's registered common stock at a price of $1.75 per share (the "July 11 Purchase Agreement").
- PR Newswire
Leap Therapeutics to Present at the 2019 Raymond James Life Sciences and MedTech Conference
CAMBRIDGE, Mass. , June 11, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today announced that Christopher K. ...
- Simply Wall St.
Investors Who Bought Leap Therapeutics (NASDAQ:LPTX) Shares A Year Ago Are Now Down 82%
The art and science of stock market investing requires a tolerance for losing money on some of the shares you buy. But...
- PR Newswire
Leap Therapeutics Reports First Quarter 2019 Financial Results
- Strong clinical trial enrollment leading to significant 2019 data - First patient enrolled in DKN-01 prostate cancer study CAMBRIDGE, Mass. , May 15, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: ...
- PR Newswire
Leap Therapeutics to Present at the 2019 Needham & Company 18th Annual Healthcare Conference
CAMBRIDGE, Mass. , April 3, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that Christopher ...
- PR Newswire
Leap Therapeutics Reports Clinical Update and 2018 Financial Results
CAMBRIDGE, Mass. , April 1, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company developing targeted and immuno-oncology therapeutics, today reported an update on its clinical ...
- PR Newswire
Leap Therapeutics Presents at Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer
CAMBRIDGE, Mass., March 18, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (LPTX) today announced the presentation of clinical data from its ongoing Phase 2 clinical trial of DKN-01 in patients with advanced gynecological malignancies at the Society of Gynecologic Oncology 50th Annual Meeting on Women's Cancer. Patients, including those with carcinosarcoma and Wnt pathway alterations, have experienced partial responses and durable clinical benefit in both the monotherapy and combination arms of the study. The complete data set will become available in the coming months as the most recently enrolled patients have yet to be evaluated.
- ACCESSWIRE
Four Tech Stocks Setting The Pace On Monday
CORAL GABLES, FL / ACCESSWIRE / March 11, 2019 / The success of the tech stock market is directly correlated to the operating assumption that tech companies are prepared to meet the rising challenges presently facing society. As we've seen in the first few months of 2019, the tech sector is booming with the excitement surrounding companies working on advanced technologies meant to take humanity into the future. ParcelPal Technology Inc (PTNYF) (PKG), Plug Power Inc (PLUG), Leap Therapeutics Inc (LPTX) and NantHealth Inc (NH) represent 4 tech stocks on the rise on Monday.
- PR Newswire
Leap Therapeutics to Present at the Society of Gynecologic Oncology 2019 Annual Meeting on Women's Cancer
CAMBRIDGE, Mass. , March 8, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (Nasdaq: LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the Company ...
- GuruFocus.com
Leap Therapeutics Inc (LPTX) CEO, President, Chairman Christopher Mirabelli Bought $999,999 of ...
CEO, President, Chairman of Leap Therapeutics Inc (NASDAQ:LPTX) Christopher Mirabelli bought 571,428 shares of LPTX on 02/05/2019 at an average price of $1.75 a share.
- PR Newswire
Leap Therapeutics Announces Closing of Public Offering and Full Exercise of Underwriters' Option to Purchase Additional Securities
CAMBRIDGE, Mass., Feb. 5, 2019 /PRNewswire/ -- Leap Therapeutics, Inc. (LPTX), a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced the closing of an underwritten public offering of 6,571,428 shares of its common stock and warrants to purchase up to 6,571,428 shares of its common stock, as well as an additional 985,714 shares of its common stock and warrants to purchase up to 985,714 shares of its common stock pursuant to the full exercise of the underwriters' option to purchase additional securities. Total gross proceeds to Leap from this offering were approximately $13,225,000, before deducting underwriting discounts and offering expenses payable by Leap, and excluding any proceeds Leap may receive upon exercise of the warrants. Raymond James & Associates, Inc. and Ladenburg Thalmann acted as book-running managers for the offering.
